Discover investment opportunities in Good Pharma Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Good Pharma Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Good Pharma Stocks To Buy using our Smart AI Filter.
10 stocks found for "Good Pharma Stocks To Buy"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.35 | ±28.9% | 6.7 | 5.29% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does Pfizer (PFE) stand out in the pharmaceutical industry?
A: Pfizer, known for its vaccine developments, benefits from a strong global presence and robust R&D pipeline, potentially positioning it for growth amidst healthcare demand. However, competition and patent expirations remain significant challenges.
Q: What should investors know about Johnson & Johnson’s (JNJ) dividend history?
A: Johnson & Johnson boasts a long history of consistent dividend payments, having increased its dividend annually for more than 50 consecutive years, appealing to income-focused investors seeking stability.
Q: What are Merck’s (MRK) primary growth drivers?
A: Merck's growth is largely driven by its oncology and vaccine segments, with Keytruda and Gardasil as top performers. Exploration into new markets and products may provide further growth opportunities.
Q: How does Bristol-Myers Squibb (BMY) approach drug development for investors looking for innovation?
A: Bristol-Myers Squibb focuses on innovative therapeutics in oncology, cardiovascular, and immunology. Its acquisition strategy complements internal developments, offering a potential edge in novel drug pipelines.
Q: What makes Eli Lilly (LLY) appealing for growth investors?
A: Eli Lilly’s focus on diabetes care, notably with Trulicity, and recent advancements in Alzheimer's and oncology therapies position the company for growth, appealing to investors seeking innovation-driven expansion.
Q: How does Novartis (NVS) maintain its competitive position in the pharmaceutical market?
A: Novartis leverages a diversified portfolio across pharmaceuticals and generics, along with strategic partnerships and acquisitions. This diversification may help mitigate risks associated with patent cliffs.
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments by the pharmaceutical industry as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country.
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read more